Skip to main content

HomeResearchCerluten

CategoryLongevity
SafetyLow Risk
StatusResearch Only

Cerluten

brain peptide bioregulator · cerebral Khavinson peptide · CNS cytomax

CategoryLongevity
Half-life
Routeoral, subcutaneous
RiskLow Risk
Providers1 listed

About Cerluten

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

A short peptide bioregulator derived from brain and CNS tissue, developed by the Khavinson Institute. Studied for cognitive support, neuroprotection, and mitigation of age-related cognitive decline.

Research Areas

neuroprotectioncognitive supportmemoryanti-aging

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Safety Notes

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

Pregnant Or Nursing

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Find Cerluten

1 provider

Frequently Asked Questions — Cerluten

A short peptide bioregulator derived from brain and CNS tissue, developed by the Khavinson Institute. Studied for cognitive support, neuroprotection, and mitigation of age-related cognitive decline.

neuroprotection, cognitive support, memory, anti-aging, longevity.

1 provider in the directory currently offers Cerluten.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.